Search

Your search keyword '"Filippatos, Gerasimos"' showing total 996 results
Start Over Author "Filippatos, Gerasimos" Publication Year Range Last 3 years
996 results on '"Filippatos, Gerasimos"'

1. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

Author

Čelutkienė, Jelena, Čerlinskaitė-Bajorė, Kamilė, Cotter, Gad, Edwards, Christopher, Adamo, Marianna, Arrigo, Mattia, Barros, Marianela, Biegus, Jan, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Léopold, Valentine, Deniau, Benjamin, Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Lam, Carolyn S. P., Voors, Adriaan A., Mebazaa, Alexandre, and Davison, Beth

Published
2024
Full Text
View/download PDF

4. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.

Author

Filippatos, Gerasimos, Anker, Stefan, August, Phyllis, Coats, Andrew, Januzzi, James, Mankovsky, Boris, Rossing, Peter, Ruilope, Luis, Pitt, Bertram, Sarafidis, Pantelis, Teerlink, John, Kapelios, Chris, Gebel, Martin, Brinker, Meike, Joseph, Amer, Lage, Andrea, Bakris, George, and Agarwal, Rajiv

Subjects
All-cause mortality, Cardiovascular mortality, Chronic kidney disease, Finerenone, Non-steroidal MRA, Type 2 diabetes, Humans, Middle Aged, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Mineralocorticoid Receptor Antagonists, Renal Insufficiency, Chronic, Heart Failure, Death, Sudden, Cardiac
Abstract

AIMS: Finerenone reduces the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We investigated the causes of mortality in the FIDELITY population. METHODS AND RESULTS: The FIDELITY prespecified pooled data analysis from FIDELIO-DKD and FIGARO-DKD excluded patients with heart failure and reduced ejection fraction. Outcomes included intention-to-treat and prespecified on-treatment analyses of the risk of all-cause and cardiovascular mortality. Of 13 026 patients [mean age, 64.8 years; mean estimated glomerular filtration rate (eGFR), 57.6 mL/min/1.73 m2], 99.8% were on renin-angiotensin system inhibitors. Finerenone reduced the incidence of all-cause and cardiovascular mortality vs. placebo (8.5% vs. 9.4% and 4.9% vs. 5.6%, respectively) and demonstrated significant on-treatment reductions [hazard ratio (HR), 0.82; 95% confidence interval (CI), 0.70-0.96; P = 0.014 and HR, 0.82; 95% CI, 0.67-0.99; P = 0.040, respectively]. Cardiovascular-related mortality was most common, and finerenone lowered the incidence of sudden cardiac death vs. placebo [1.3% (incidence rate 0.44/100 patient-years) vs. 1.8% (0.58/100 patient-years), respectively; HR, 0.75; 95% CI, 0.57-0.996; P = 0.046]. The effects of finerenone on mortality were similar across all Kidney Disease: Improving Global Outcomes risk groups. Event probability with finerenone at 4 years was consistent irrespective of baseline urine albumin-to-creatinine ratio, but seemingly more pronounced in patients with higher baseline eGFR. CONCLUSION: In FIDELITY, finerenone significantly reduced the risk of all-cause and cardiovascular mortality vs. placebo in patients with T2D across a broad spectrum of CKD stages while on treatment, as well as sudden cardiac death in the intention-to-treat population. CLINICAL TRIALS REGISTRATION: FIDELIO-DKD and FIGARO-DKD are registered with ClinicalTrials.gov, numbers NCT02540993 and NCT02545049, respectively (funded by Bayer AG).

Published
2023

5. Implications of worsening renal function before hospitalization for acute heart failure

Author

Wettersten, Nicholas, Duff, Stephen, Horiuchi, Yu, Veldhuisen, Dirk J, Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C, Cannon, Chad M, Müeller, Gerhard A, Birkhahn, Robert, Taub, Pam, Vilke, Gary M, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Maisel, Alan, Murray, Patrick T, and Ix, Joachim H

Subjects
Kidney Disease, Heart Disease, Clinical Research, Cardiovascular, Patient Safety, Renal and urogenital, Humans, Kidney, Creatinine, Acute Disease, Biomarkers, Heart Failure, Hospitalization, Acute heart failure, Acute kidney injury, Cardiorenal syndrome, Cardiorespiratory Medicine and Haematology
Abstract

AimsKidney function changes dynamically during AHF treatment, but risk factors for and consequences of worsening renal function (WRF) at hospital admission are uncertain. We aimed to determine the significance of WRF at admission for acute heart failure (AHF).Methods and resultsWe evaluated a subgroup of 406 patients from The Acute Kidney Injury Neutrophil gelatinase-associated lipocalin Evaluation of Symptomatic heart failure Study (AKINESIS) who had serum creatinine measurements available within 3 months before and at the time of admission. Admission WRF was primarily defined as a 0.3 mg/dL or 50% creatinine increase from preadmission. Alternative definitions evaluated were a ≥0.5 mg/dL creatinine increase, ≥25% glomerular filtration rate decrease, and an overall change in creatinine. Predictors of admission WRF were evaluated. Outcomes evaluated were length of hospitalization, a composite of adverse in-hospital events, and the composite of death or HF readmission at 30, 90, and 365 days. Biomarkers' prognostic ability for these outcomes were evaluated in patients with admission WRF. One-hundred six patients (26%) had admission WRF. These patients had features of more severe AHF with lower blood pressure, higher BUN, and lower serum sodium concentrations at admission. Higher BNP (odds ratio [OR] per doubling 1.16-1.28, 95% confidence interval [CI] 1.00-1.55) and lower diastolic blood pressure (OR 0.97-0.98, 95% CI 0.96-0.99) were associated with a higher odds for the three definitions of admission WRF. The primary WRF definition was not associated with a longer hospitalization, but alternative WRF definitions were (1.3 to 1.6 days longer, 95% CI 1.0-2.2). WRF across definitions was not associated with a higher odds of adverse in-hospital events or a higher risk of death or HF readmission. In the subset of patients with WRF, biomarkers were not prognostic for any outcome.ConclusionsAdmission WRF is common in AHF patients and is associated with an increased length of hospitalization, but not adverse in-hospital events, death, or HF readmission. Among those with admission WRF, biomarkers did not risk stratify for adverse events.

Published
2023

9. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk

Author

Ambrosy, Andrew P., Chang, Alex J., Davison, Beth, Voors, Adriaan, Cohen-Solal, Alain, Damasceno, Albertino, Kimmoun, Antoine, Lam, Carolyn S.P., Edwards, Christopher, Tomasoni, Daniela, Gayat, Etienne, Filippatos, Gerasimos, Saidu, Hadiza, Biegus, Jan, Celutkiene, Jelena, Ter Maaten, Jozine M., Čerlinskaitė-Bajorė, Kamilė, Sliwa, Karen, Takagi, Koji, Metra, Marco, Novosadova, Maria, Barros, Marianela, Adamo, Marianna, Pagnesi, Matteo, Arrigo, Mattia, Chioncel, Ovidiu, Diaz, Rafael, Pang, Peter S., Ponikowski, Piotr, Cotter, Gad, and Mebazaa, Alexandre

Published
2024
Full Text
View/download PDF

10. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial

Author

Arrigo, Mattia, Davison, Beth, Edwards, Christopher, Adamo, Marianna, Ambrosy, Andrew P., Barros, Marianela, Biegus, Jan, Celutkiene, Jelena, Čerlinskaitė-Bajorė, Kamilė, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Lam, Carolyn S.P., Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Voors, Adriaan A., Cotter, Gad, and Mebazaa, Alexandre

Published
2024
Full Text
View/download PDF

11. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure

Author

de Koning, Marie-Sophie L. Y., Emmens, Johanna E., Romero-Hernández, Esteban, Bourgonje, Arno R., Assa, Solmaz, Figarska, Sylwia M., Cleland, John G. F., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., Metra, Marco, Filippatos, Gerasimos S., van Veldhuisen, Dirk J., Anker, Stefan D., Dickstein, Kenneth, Voors, Adriaan A., Lipsic, Erik, van Goor, Harry, and van der Harst, Pim

Published
2023
Full Text
View/download PDF

12. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

Author

Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Fonarow, Gregg C, Greene, Stephen J, Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J Stewart, Anker, Stefan D, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Heart Disease, Good Health and Well Being, Glucose, Heart Failure, Humans, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Symporters, Fragility index, Robustness, Sodium-glucose co-transporter 2 inhibitors, Cardiac failure, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsRecent trials have evaluated sodium-glucose co-transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).Methods and resultsFragility index is defined as the minimum number of patients that must be moved from the 'non-event' to the 'event' group to turn a statistically significant result to non-significant. In addition to FI, fragility quotient [(FQ); FI divided by the sample size] was calculated to assess the proportion of events that must be moved to change the significance. For statistically non-significant outcomes, reverse fragility index (RFI) and reverse fragility quotient (RFQ) were calculated. Robustness of findings after pooling data from all three trials was also assessed. A robust reduction in first HF hospitalization or cardiovascular mortality was seen with dapagliflozin (FI = 62 and FQ = 0.013), empagliflozin (FI = 50 and FQ = 0.013), and sotagliflozin (FI = 60 and FQ = 0.049). Dapagliflozin nominally improved all-cause and cardiovascular mortality, with modest FI (n = 8 and 5) and FQ (0.002 and 0.001). Empagliflozin and sotagliflozin did not demonstrate statistically significant reductions in all-cause mortality, with modest RFI (empagliflozin: RFI = 26 and RFQ = 0.007; sotagliflozin: RFI = 6 and RFQ = 0.005). A similar trend was seen with cardiovascular mortality (empagliflozin: RFI = 24 and RFQ = 0.006; sotagliflozin: RFI = 7 and RFQ = 0.006). Upon meta-analysis, the result for first HF hospitalization or cardiovascular mortality was robust (FI = 95 and FQ = 0.010). The reductions in all-cause (FI = 12 and FQ = 0.001) and cardiovascular mortality (FI = 9 and FQ = 0.001), while statistically significant, were fragile.ConclusionImprovement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality to fully understand the benefit of therapies on fatal events.

Published
2022

13. Performance of Different Risk Scores for the Detection of Atrial Fibrillation Among Patients With Cryptogenic Stroke

Author

Palaiodimou, Lina, Theodorou, Aikaterini, Triantafyllou, Sokratis, Dilaveris, Polychronis, Flevari, Panagiota, Giannopoulos, Georgios, Kossyvakis, Charalampos, Adreanides, Elias, Tympas, Konstantinos, Nikolopoulos, Petros, Zompola, Christina, Bakola, Eleni, Chondrogianni, Maria, Magiorkinis, Gkikas, Deftereos, Spyridon, Giannopoulos, Sotirios, Tsioufis, Konstantinos, Filippatos, Gerasimos, and Tsivgoulis, Georgios

Published
2024
Full Text
View/download PDF

14. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial

Author

TOMASONI, DANIELA, DAVISON, BETH, ADAMO, MARIANNA, PAGNESI, MATTEO, MEBAZAA, ALEXANDRE, EDWARDS, CHRISTOPHER, ARRIGO, MATTIA, BARROS, MARIANELA, BIEGUS, JAN, ČELUTKIENĖ, JELENA, ČERLINSKAITĖ-BAJORĖ, KAMILĖ, CHIONCEL, OVIDIU, COHEN-SOLAL, ALAIN, DAMASCENO, ALBERTINO, DIAZ, RAFAEL, FILIPPATOS, GERASIMOS, GAYAT, ETIENNE, KIMMOUN, ANTOINE, LAM, CAROLYN S.P., NOVOSADOVA, MARIA, PANG, PETER S., PONIKOWSKI, PIOTR, SAIDU, HADIZA, SLIWA, KAREN, TAKAGI, KOJI, MAATEN, JOZINE M. TER, VOORS, ADRIAAN, COTTER, GAD, and METRA, MARCO

Published
2024
Full Text
View/download PDF

15. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Author

Rosano, Giuseppe, Ponikowski, Piotr, Vitale, Cristiana, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Filippatos, Gerasimos, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Ruschitzka, Frank, Kumpeson, Vasuki, Goehring, Udo-Michael, van der Meer, Peter, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

16. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

Author

Tomasoni, Daniela, Fonarow, Gregg C, Adamo, Marianna, Anker, Stefan D, Butler, Javed, Coats, Andrew JS, Filippatos, Gerasimos, Greene, Stephen J, McDonagh, Theresa A, Ponikowski, Piotr, Rosano, Giuseppe, Seferovic, Petar, Vaduganathan, Muthiah, Voors, Adriaan A, and Metra, Marco

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Diabetes, Cardiovascular, Heart Disease, Clinical Research, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, Metabolic and endocrine, Good Health and Well Being, Diabetes Mellitus, Type 2, Glucose, Heart Failure, Humans, Quality of Life, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume, Symporters, Heart failure with reduced ejection fraction, Sodium-glucose co-transporter 2 inhibitors, Dapagliflozin, Empagliflozin, Sotagliflozin, Medical therapy, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical practice guidelines have recommended dapagliflozin or empagliflozin in all patients with HFrEF, or sotagliflozin in those with HFrEF and concomitant diabetes, the timing and practical integration of these drugs in clinical practice is less well defined. We propose that these drugs are candidates for early, upfront administration to patients with newly diagnosed HFrEF and for patients hospitalized with HF. Growing evidence has established early benefits, with clinically meaningful reductions in clinical events that reach statistical significance within days to weeks, following dapagliflozin, empagliflozin or, in diabetic patients, sotagliflozin initiation. Secondly, although major clinical trials have tested these drugs in patients already receiving background HF therapy, secondary analyses showed that their efficacy is independent of that. Third, SGLT2 inhibitors are generally safe and well tolerated, with clinical trial data reporting minimal effects on blood pressure, glycaemia-related adverse events, and no excess in acute kidney injury. Rather, they exert renal protective effects and reduce risk of hyperkalaemia, properties that favour initiation, tolerance and persistence of renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists. This review supports the early initiation of dapagliflozin and empagliflozin (or sotagliflozin limited to patients with diabetes) to rapidly improve clinical outcome and quality of life of HFrEF patients.

Published
2022

18. Implementation of a cardiogenic shock team in a tertiary academic center

Author

Karamasis, Grigoris V., Polyzogopoulou, Effie, Varlamos, Charalampos, Frantzeskaki, Frantzeska, Dragona, Vassiliki-Maria, Boultadakis, Antonios, Bistola, Vasiliki, Fountoulaki, Katerina, Pappas, Christos, Kolokathis, Fotios, Pavlopoulos, Dionysios, Toumpoulis, Ioannis K., Kollias, Vasilios D., Farmakis, Dimitrios, Rallidis, Loukianos S., Angouras, Dimitrios C., Tsangaris, Iraklis, Parissis, John T., and Filippatos, Gerasimos

Published
2024
Full Text
View/download PDF

19. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper

Author

Lala, Anuradha, Hamo, Carine E., Bozkurt, Biykem, Fiuzat, Mona, Blumer, Vanessa, Bukhoff, Daniel, Butler, Javed, Costanzo, Maria Rosa, Felker, G. Michael, Filippatos, Gerasimos, Konstam, Marvin A., McMurray, John J.V., Mentz, Robert J., Metra, Marco, Psotka, Mitchell A., Solomon, Scott D., Teerlink, John, Abraham, William T., and O’Connor, Christopher M.

Published
2024
Full Text
View/download PDF

21. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

Author

Savarese, Gianluigi, Gatti, Paolo, Benson, Lina, Adamo, Marianna, Chioncel, Ovidiu, Crespo-Leiro, Maria G., Anker, Stefan D., Coats, Andrew J.S., Filippatos, Gerasimos, Lainscak, Mitja, McDonagh, Theresa, Mebazaa, Alexandre, Metra, Marco, Piepoli, Massimo F., Rosano, Giuseppe M.C., Ruschitzka, Frank, Seferovic, Petar, Volterrani, Maurizio, Maggioni, Aldo P., and Lund, Lars H.

Published
2024
Full Text
View/download PDF

23. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

Author

Gerhardt, Teresa, Gerhardt, Louisa M S, Ouwerkerk, Wouter, Roth, Gregory A, Dickstein, Kenneth, Collins, Sean P, Cleland, John G F, Dahlstrom, Ulf, Tay, Wan Ting, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Lam, Carolyn S P, Tromp, Jasper, and Angermann, Christiane E

Published
2023
Full Text
View/download PDF

24. Cardiorenal multimorbidity in hospitalized cardiology patients: The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study

Author

Leontsinis, Ioannis, Farmakis, Dimitrios, Avramidis, Dimitrios, Andrikou, Eirini, Valatsou, Angeliki, Gartzonikas, Elias, Doundoulakis, Ioannis, Zarifis, Ioannis, Karpouzis, Ioannis, Kafkala, Kristalenia, Kouvelas, Nikos, Kourek, Christos, Koufou, Eleni, Kochiadakis, George, Kifnidis, Konstantinos, Liori, Sotiria, Manolis, George, Marketou, Maria, Moschos, Nikitas, Bampatsias, Dimitrios, Bibis, George, Bonou, Maria, Naka, Aikaterini, Davlouros, Periklis, Ntalakouras, Ioannis, Papakonstantinou, Panteleimon Ε., Pappa, Evgenia, Patsilinakos, Sotirios, Plaitis, Aristeidis, Sideris, Antonios, Sideris, Skevos, Skoularigis, John, Stamatelopoulos, Kimon, Stefanou, Garyfallia, Tziakas, Dimitrios, Chatzieleftheriou, Christos, Chrysochoou, Christina, Filippatos, Gerasimos, and Tsioufis, Costas

Published
2023
Full Text
View/download PDF

27. Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial

Author

Wilkoff, Bruce L, Filippatos, Gerasimos, Leclercq, Christophe, Gold, Michael R, Hersi, Ahmad S, Kusano, Kengo, Mullens, Wilfried, Felker, G Michael, Kantipudi, Charan, El-Chami, Mikhael F, Essebag, Vidal, Pierre, Bertrand, Philippon, Francois, Perez-Gil, Francisco, Chung, Eugene S, Sotomonte, Juan, Tung, Stanley, Singh, Balbir, Bozorgnia, Babak, Goel, Satish, Ebert, Hans Holger, Varma, Niraj, Quan, Kara J, Salerno, Fiorella, Gerritse, Bart, van Wel, Janelle, Schaber, Daniel E, Fagan, Dedra H, and Birnie, David

Published
2023
Full Text
View/download PDF

28. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry

Author

Tromp, Jasper, Ezekowitz, Justin A., Ouwerkerk, Wouter, Chandramouli, Chanchal, Yiu, Kai Hang, Angermann, Christiane E., Dahlstrom, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V., Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Collins, Sean P., Filippatos, Gerasimos, Cleland, John G.F., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

31. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials

Author

Dimond, Matthew, Khan, Mohammad S, Fiuzat, Mona, Cleland, John G, Bhatt, Ankeet, Psotka, Mitchell, Anker, Stefan D, Butler, Javed, Felker, Michael, Mark, Daniel B, Carson, Peter E, Abraham, William T, Ahmad, Tariq, Lindenfeld, Joann, Vaduganathan, Muthiah, Whellan, David J, Vardeny, Orly, Solomon, Scott, Lewis, Eldrin F, Filippatos, Gerasimos, and OConnor, Christopher M

Published
2023
Full Text
View/download PDF

32. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Author

Anker, Stefan D., Butler, Javed, Usman, Muhammad Shariq, Filippatos, Gerasimos, Ferreira, João Pedro, Bocchi, Edimar, Böhm, Michael, Rocca, Hans Pieter Brunner-La, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L., González-Juanatey, José R., Merkely, Bela, Nicholls, Stephen J., Perrone, Sergio V., Piña, Ileana L., Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Iwata, Tomoko, Schnee, Janet M., Brueckmann, Martina, Pocock, Stuart J., and Zannad, Faiez

Published
2022
Full Text
View/download PDF

33. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations

Author

Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Anker, Stefan D., Bakris, George L., Bhatt, Deepak L., Filippatos, Gerasimos, Fonarow, Gregg C., Greene, Stephen J., Januzzi, James L., Jr, Khan, Muhammad Shahzeb, Kosiborod, Mikhail N., McGuire, Darren K., Piña, Ileana L., Rosenstock, Julio, Vaduganathan, Muthiah, Verma, Subodh, Zieroth, Shelley, and Butler, Javed

Published
2023
Full Text
View/download PDF

35. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Author

Tsutsui, HIROYUKI, ALBERT, NANCY M., COATS, ANDREW J.S., ANKER, STEFAN D., BAYES-GENIS, ANTONI, BUTLER, JAVED, CHIONCEL, OVIDIU, DEFILIPPI, CHRISTOPHER R., DRAZNER, MARK H., FELKER, G. MICHAEL, FILIPPATOS, GERASIMOS, FIUZAT, MONA, IDE, TOMOMI, JANUZZI, JAMES L., Jr, KINUGAWA, KOICHIRO, KUWAHARA, KOICHIRO, MATSUE, YUYA, MENTZ, ROBERT J., METRA, MARCO, PANDEY, AMBARISH, ROSANO, GIUSEPPE, SAITO, YOSHIHIKO, SAKATA, YASUSHI, SATO, NAOKI, SEFEROVIC, PETAR M., TEERLINK, JOHN, YAMAMOTO, KAZUHIRO, and YOSHIMURA, MICHIHIRO

Published
2023
Full Text
View/download PDF

38. Galectin-3, Acute Kidney Injury and Myocardial Damage in Patients With Acute Heart Failure

Author

HORIUCHI, YU, WETTERSTEN, NICHOLAS, VAN VELDHUISEN, DIRK J., MUELLER, CHRISTIAN, FILIPPATOS, GERASIMOS, NOWAK, RICHARD, HOGAN, CHRISTOPHER, KONTOS, MICHAEL C., CANNON, CHAD M., MÜELLER, GERHARD A., BIRKHAHN, ROBERT, TAUB, PAM, VILKE, GARY M., MCDONALD, KENNETH, MAHON, NIALL, NUÑEZ, JULIO, BRIGUORI, CARLO, PASSINO, CLAUDIO, DUFF, STEPHEN, MAISEL, ALAN, and MURRAY, PATRICK T.

Published
2023
Full Text
View/download PDF

41. Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study

Author

Ikonomidis, Ignatios, Thymis, John, Simitsis, Panagiotis, Koliou, Georgia-Angeliki, Katsanos, Spiridon, Triantafyllou, Charilaos, Kousathana, Foteini, Pavlidis, George, Kountouri, Aikaterini, Polyzogopoulou, Eftihia, Katogiannis, Konstantinos, Vlastos, Dimitrios, Kostelli, Gavriella, Triantafyllidi, Helen, Parissis, John, Papadavid, Evangelia, Lekakis, John, Filippatos, Gerasimos, and Lambadiari, Vaia

Published
2022
Full Text
View/download PDF

43. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis

Author

Filippatos, Gerasimos, Ponikowski, Piotr, Farmakis, Dimitrios, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Rosano, Giuseppe, Ruschitzka, Frank, van der Meer, Peter, Waechter, Sandra, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

46. Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial and comparison to COAPT and MITRA‐FR trials

Author

Anker, Stefan D., primary, Friede, Tim, additional, von Bardeleben, Ralph Stephan, additional, Butler, Javed, additional, Khan, Muhammad Shahzeb, additional, Diek, Monika, additional, Heinrich, Jutta, additional, Geyer, Martin, additional, Placzek, Marius, additional, Ferrari, Roberto, additional, Abraham, William T., additional, Alfieri, Ottavio, additional, Auricchio, Angelo, additional, Bayes‐Genis, Antoni, additional, Cleland, John G.F., additional, Filippatos, Gerasimos, additional, Gustafsson, Finn, additional, Haverkamp, Wilhelm, additional, Kelm, Malte, additional, Kuck, Karl‐Heinz, additional, Landmesser, Ulf, additional, Maggioni, Aldo P., additional, Metra, Marco, additional, Ninios, Vlasis, additional, Petrie, Mark C., additional, Rassaf, Tienush, additional, Ruschitzka, Frank, additional, Schäfer, Ulrich, additional, Schulze, P. Christian, additional, Spargias, Konstantinos, additional, Vahanian, Alec, additional, Zamorano, Jose Luis, additional, Zeiher, Andreas, additional, Karakas, Mahir, additional, Koehler, Friedrich, additional, Lainscak, Mitja, additional, Öner, Alper, additional, Mezilis, Nikolaos, additional, Theofilogiannakos, Efstratios K, additional, Ninios, Ilias, additional, Chrissoheris, Michael, additional, Kourkoveli, Panagiota, additional, Papadopoulos, Konstantinos, additional, Smolka, Grzegorz, additional, Wojakowski, Wojciech, additional, Reczuch, Krzysztof, additional, Pinto, Fausto J., additional, Zmudka, Krzysztof, additional, Kalarus, Zbigniew, additional, Adamo, Marianna, additional, Santiago‐Vacas, Evelyn, additional, Ruf, Tobias Friedrich, additional, Gross, Michael, additional, Tongers, Joern, additional, Hasenfuß, Gerd, additional, Schillinger, Wolfgang, additional, and Ponikowski, Piotr, additional

Published
2024
Full Text
View/download PDF

48. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Author

Handelsman, Yehuda, primary, Anderson, John E., additional, Bakris, George L., additional, Ballantyne, Christie M., additional, Bhatt, Deepak L., additional, Bloomgarden, Zachary T., additional, Bozkurt, Biykem, additional, Budoff, Matthew J., additional, Butler, Javed, additional, Cherney, David Z.I., additional, DeFronzo, Ralph A., additional, Del Prato, Stefano, additional, Eckel, Robert H., additional, Filippatos, Gerasimos, additional, Fonarow, Gregg C., additional, Fonseca, Vivian A., additional, Garvey, W. Timothy, additional, Giorgino, Francesco, additional, Grant, Peter J., additional, Green, Jennifer B., additional, Greene, Stephen J., additional, Groop, Per-Henrik, additional, Grunberger, George, additional, Jastreboff, Ania M., additional, Jellinger, Paul S., additional, Khunti, Kamlesh, additional, Klein, Samuel, additional, Kosiborod, Mikhail N., additional, Kushner, Pamela, additional, Leiter, Lawrence A., additional, Lepor, Norman E., additional, Mantzoros, Christos S., additional, Mathieu, Chantal, additional, Mende, Christian W., additional, Michos, Erin D., additional, Morales, Javier, additional, Plutzky, Jorge, additional, Pratley, Richard E., additional, Ray, Kausik K., additional, Rossing, Peter, additional, Sattar, Naveed, additional, Schwarz, Peter E.H., additional, Standl, Eberhard, additional, Steg, P. Gabriel, additional, Tokgözoğlu, Lale, additional, Tuomilehto, Jaakko, additional, Umpierrez, Guillermo E., additional, Valensi, Paul, additional, Weir, Matthew R., additional, Wilding, John, additional, and Wright, Eugene E., additional

Published
2024
Full Text
View/download PDF

49. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC

Author

Rosano, Giuseppe M.C., primary, Stolfo, Davide, additional, Anderson, Lisa, additional, Abdelhamid, Magdy, additional, Adamo, Marianna, additional, Bauersachs, Johann, additional, Bayes‐Genis, Antoni, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Filippatos, Gerasimos, additional, Hill, Loreena, additional, Lainscak, Mitja, additional, Lambrinou, Ekaterini, additional, Maas, Angela H.E.M., additional, Massouh, Angela R., additional, Moura, Brenda, additional, Petrie, Mark C., additional, Rakisheva, Amina, additional, Ray, Robin, additional, Savarese, Gianluigi, additional, Skouri, Hadi, additional, Van Linthout, Sophie, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Metra, Marco, additional, and Coats, Andrew J.S., additional

Published
2024
Full Text
View/download PDF

50. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

Author

Solomon, Scott D., primary, Ostrominski, John W., additional, Vaduganathan, Muthiah, additional, Claggett, Brian, additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Pitt, Bertram, additional, Senni, Michele, additional, Shah, Sanjiv J., additional, Voors, Adriaan A., additional, Zannad, Faiez, additional, Abidin, Imran Zainal, additional, Alcocer‐Gamba, Marco Antonio, additional, Atherton, John J., additional, Bauersachs, Johann, additional, Ma, Chang‐Sheng, additional, Chiang, Chern‐En, additional, Chioncel, Ovidiu, additional, Chopra, Vijay, additional, Comin‐Colet, Josep, additional, Filippatos, Gerasimos, additional, Fonseca, Cândida, additional, Gajos, Grzegorz, additional, Goland, Sorel, additional, Goncalvesová, Eva, additional, Kang, Seok‐Min, additional, Katova, Tzvetana, additional, Kosiborod, Mikhail N., additional, Latkovskis, Gustavs, additional, Lee, Alex Pui‐Wai, additional, Linssen, Gerard C.M., additional, Llamas‐Esperón, Guillermo, additional, Mareev, Vyacheslav, additional, Martinez, Felipe A., additional, Melenovský, Vojtěch, additional, Merkely, Béla, additional, Nodari, Savina, additional, Petrie, Mark C., additional, Saldarriaga, Clara Inés, additional, Saraiva, Jose Francisco Kerr, additional, Sato, Naoki, additional, Schou, Morten, additional, Sharma, Kavita, additional, Troughton, Richard, additional, Udell, Jacob A., additional, Ukkonen, Heikki, additional, Vardeny, Orly, additional, Verma, Subodh, additional, von Lewinski, Dirk, additional, Voronkov, Leonid G., additional, Yilmaz, Mehmet Birhan, additional, Zieroth, Shelley, additional, Lay‐Flurrie, James, additional, van Gameren, Ilse, additional, Amarante, Flaviana, additional, Viswanathan, Prabhakar, additional, and McMurray, John J.V., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results